Home > Journals > Minerva Pediatrica > Past Issues > Articles online first > Minerva Pediatrica 2017 Jun 22

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Cite this article as

 

 

Minerva Pediatrica 2017 Jun 22

DOI: 10.23736/S0026-4946.17.04910-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

The impact of vitamin D supplementation on serum cathelicidin levels and the clinical course of atopic dermatitis in children

Kyriaki TSOTRA 1 , Anastasia GAROUFI 1, Lydia KOSSIVA 1, Dimitrios GOURGIOTIS 2, Theano TSOUKATOU 1, Eleni KATSANTONI 3, Panagiotis STAVROPOULOS 4

1 Second Department of Pediatrics, Aglaia Kyriakou University Hospital, National and Kapodistrian University of Athens, Athens, Greece; 2 Laboratory of Clinical Biochemistry-Molecular Diagnosis, Aglaia Kyriakou University Hospital, National and Kapodistrian University of Athens, Athens, Greece; 3 Basic Research Center, Biomedical Research Foundation, Academy of Athens, Athens, Greece; 4 Department of Dermatology, Andreas Sygros Hospital, Athens, Greece


PDF


BACKGROUND: Cathelicidin has been correlated with the pathophysiology of atopic dermatitis (AD). An indirect correlation of vitamin D with the course of the disease has already been reported as it directly affects the levels of cathelicidin. The purpose of the present article is to investigate the impact of vitamin D supplementation on the course of AD.
METHODS: We conducted a prospective observational study. The severity of AD was assessed with the clinical tool SCORAD (SCORing Atopic Dermatitis) which is developed by the European Task Force on AD.
RESULTS: Fifty children with AD were enrolled and stratified in two groups based on the severity of SCORAD. Children with severe AD (SCORAD index> 40) received higher doses of vitamin D in order to sufficiently reduce the disease (comparable index SCORAD children with mild atopic dermatitis). While the baseline SCORAD differed statistically significant level between the two groups of children with AD (p <.001) this difference disappeared at 20 (p = .649) days and remained statistically insignificant both at 45 days (p = .610), and at the end of the administration of treatment (p = .474) (Table). This effect was based on a significant downregulation of the severity of symptoms in the group of children that received 2400 IU of vitamin D.
CONCLUSIONS: The findings of our study suggest that vitamin D may be accurately used in current clinical practice for the management of AD. However, the recommended dose should be titrated taking in mind the severity of the disease.


KEY WORDS: Atopic dermatitis - Cathelicidin - LL-37 - hCAP18 - Vitamin D

top of page